Summary
Introduction
The autosomal dominant cerebellar ataxias (ADCAs) are a heterogeneous group of dominantly inherited disorders characterized by progressive ataxia that results from degeneration of the cerebellum and its afferent and efferent connections. Although manifestations of cerebellar disease are predominant in ADCA, there is often clinical and neuropathological evidence for involvement of the brainstem, basal ganglia, pyramidal tract, somatosensory spinal pathways, optic nerve and peripheral nervous system (Greenfield, 1954; Harding, 1982) .
The ADCAs have been divided into several clinical types, the most common of which, ADCA-I, is characterized by supranuclear ophthalmoplegia, optic atrophy, basal ganglia symptoms, dementia and amyotrophy. ADCA-II is distinct © Oxford University Press 1997 patients, but only in a minority of SCA2 and SCA3 patients. In contrast, somatosensory evoked potentials were delayed or absent in the majority of patients with no significant differences between the mutations. Abnormalities of brainstem auditory evoked potentials were found in about half of the patients irrespective of the underlying mutation. In addition, reduced sensory nerve action potentials, suggesting sensory axonal neuropathy were found in all three mutations. These findings provide electrophysiological evidence that pyramidal and visual pathways are differentially affected in SCA1, SCA2 and SCA3 patients. in having the additional feature of retinal degeneration, whereas ADCA-III is characterized by a purely cerebellar syndrome (Harding, 1982) . Genetic heterogeneity of ADCA-I has been established, with disease loci assigned to chromosomes 6p (spinocerebellar ataxia type 1, SCA1); 12 q (type 2, SCA2), 14q (type 3, SCA3), 16q (type 4, SCA4) and 19p (type 6, SCA6) (Zoghbi et al., 1991; Gispert et al., 1993; Stevanin et al., 1994; Flanigan et al., 1996; Zhuchenko et al., 1997) . Four of the genes, corresponding to SCA1, SCA2, SCA3 and SCA6 have been isolated, and the mutations have been shown to be unstable trinucleotide (CAG) repeat expansions within coding regions of the respective genes (Orr et al., 1993; Kawaguchi et al., 1994; Imbert et al., 1996; Pulst et al., 1996; Sanpei et al., 1996) . In families with an almost pure cerebellar syndrome suggestive of ADCA-III disease, loci have been found on chromosome 11cen (SCA5) and 19p (SCA6) (Ranum et al., 1994; Zhuchenko et al., 1997) , while the locus for ADCA-II, SCA7 has been assigned to chromosome 3p (Benomar et al., 1995) .
The identification of various disease loci underlying ADCA-I raises the question whether the different mutations cause distinct phenotypes. A number of distinguishing clinical features have been noted in the most common mutations, SCA1, SCA2 and SCA3. These involve pyramidal tract signs, pale discs and dysphagia in SCA1, saccade slowing and signs of peripheral neuropathy in SCA2, and prominent eyes and features of basal ganglia dysfunction in SCA3 (Orozco et al., 1990; Lopes-Cendes et al., 1994; Dürr et al., 1995) . Nevertheless, there is considerable overlap of the clinical syndromes of SCA1, SCA2 and SCA3. We have recently reported that SCA2 and SCA3 can be distinguished in vivo by recording eye movements and using morphometric magnetic resonance imaging analysis (Bürk et al., 1996) ; SCA2 was characterized by severe saccade slowing and imaging changes typical for olivopontocerebellar atrophy with severe shrinkage of the middle cerebellar peduncles. In SCA3, saccade velocity was almost normal and infratentorial atrophy was mild, while SCA1 patients fell in an intermediate range that overlapped with both SCA2 and SCA3 (Bürk et al., 1996) .
The present study was undertaken to extend the genotypephenotype correlation analysis in ADCA-I by studying involvement of the peripheral nervous system, pyramidal tracts and sensory pathways using electrophysiological methods. To this end, we performed nerve conduction studies and recorded visual evoked potentials (VEPs), somatosensory evoked potentials (SEPs), brainstem auditory evoked potentials (BAEPs) and motor evoked potentials following transcranial magnetic stimulation (MEPs) in patients with the SCA1, SCA2 and SCA3 mutations.
Patients and methods Patients
Twenty-five families with a molecular diagnosis of SCA1, SCA2 or SCA3 were selected from the Tübingen ataxia database. At present, this database includes 58 ADCA families. All patients included in this paper (n ϭ 41) fulfilled the diagnostic criteria of ADCA-I which were as follows. (i) Progressive, otherwise unexplained, ataxia in association with at least one of the following signs: saccade slowing, ophthalmoplegia, spasticity, extensor plantar responses, decreased vibration sense or dystonia; and (ii) autosomal dominant inheritance. All patients were personally interviewed and examined clinically using a standardized examination procedure. Severity of cerebellar symptoms was rated on a scale ranging from zero (absent) to five (most severe) (Klockgether et al., 1990) .
Detection of the CAG expansions at the SCA1, SCA2 and SCA3 loci was performed using polymerase chain reaction as described in detail elsewhere (Orr et al., 1993; Kawaguchi et al., 1994; Bürk, et al., 1996; Imbert, et al., 1996) . All patients gave informed consent to participate in the study which was approved by the local ethics committee at Tübingen.
Electrophysiological studies
Motor (tibial) nerve conduction velocity was measured using standard neurographic procedures. Sensory nerve conduction velocity was measured following antidromic stimulation of the sural nerve. Skin temperature was routinely controlled, and the extremities were warmed if necessary. Nerve conduction velocities below the 3 SD threshold of normal control data from our laboratory, amplitudes of compound muscle potentials below 5 mV and sensory nerve action potentials below 10 µV were considered abnormal.
VEPs were recorded from Oz electrode against a reference electrode placed on an ear following transient 22.5 o checkerboard stimulation at 0.8 Hz. Sixty-four recordings were averaged twice and the latency and amplitude of P100 were measured.
MEPs were recorded from the abductor hallucis brevis muscle with surface electrodes after transcranial magnetic stimulation of the brain. Stimuli of suprathreshold intensity were applied to the scalp with the coil centred over Fz. If potentials were not evoked, the intensity was raised to values which evoke potentials in Ͼ99 % of normal individuals. Central motor conduction time was determined using the Fwave technique.
Cortical SEPs were recorded from Cz' (2 cm dorsal to Cz), against Fz, following tibial nerve stimulation with bipolar surface electrodes placed at the ankles. Rectangular pulses of 0.1 ms were delivered at 3 Hz and at a stimulus intensity of 4 mA above motor threshold. A total of 1024 sweeps were averaged in two sessions of 512, with bandpass filters at 10 Hz and 1 kHz. The latency of P40 was measured.
BAEPs were recorded simultaneously from both mastoids against a Cz reference electrode following rarefaction-click stimulation with pulses of 0.1 ms delivered monaurally at 70 dB above hearing threshold and at 11.9 Hz. In some instances additional stimulation with alternating polarity was performed to enhance peak I. A total of 2048 sweeps were averaged with bandpass filters at 100 Hz and 3 kHz. Latencies of waves I, III and V and interpeak intervals I-III, I-V and III-V were measured.
Latencies beyond the 3 SD threshold for the normal data from our laboratory and absence of evoked potentials were considered abnormal.
Neither nerve conduction nor evoked potential studies yielded significant right-left differences in any of the groups. We therefore arbitrarily chose the right side for further analysis.
Statistical analysis
Statistical analysis was performed individual by individual. Statistical analysis of the electrophysiological data was Fig. 1 Percentage of abnormal P100 responses in VEPs in SCA1, SCA2 and SCA3 patients. VEPs were recorded in nine SCA1, 11 SCA2 and 16 SCA3 patients. Abnormal P100 responses were significantly more frequent in SCA1 than in SCA3 patients. ** P Ͻ 0.01 versus SCA3 patients. performed using the χ 2 test (frequency of abnormal results) or analysis of variance (ANOVA) followed by a Tukey test (quantitative data). Clinical data were compared using the Kruskal-Wallis test (cerebellar rating) and the χ 2 test (frequency of associated symptoms).
Results

Clinical characteristics
Mean age of disease onset in the affected individuals was 34.2 Ϯ 9.0 years in SCA1 (n ϭ 9), 35.4 Ϯ 10.0 years in SCA2 (n ϭ 14) and 41.7 Ϯ 14.5 years in SCA3 patients (n ϭ 18). Disease duration was 8.9 Ϯ 7.0 years in SCA1, 9.0 Ϯ 4.4 years in SCA2 and 7.9 Ϯ 4.8 years in SCA3 patients. There were no significant differences between the groups.
All patients presented with a cerebellar syndrome. Severity of ataxia of gait, stance and lower limbs was similar in all groups. However, ataxia of upper limbs (P Ͻ 0.001), action tremor (P Ͻ 0.01), dysarthria (P Ͻ 0.01) and dysdiadochokinesis (P Ͻ 0.05) were more severe in SCA2 compared with SCA3. Dysarthria was more severe in SCA1 compared with SCA3 (P Ͻ 0.05). Non-cerebellar symptoms, including decreased or absent ankle reflexes (P Ͻ 0.01 versus SCA2, P Ͻ 0.05 versus SCA3) and double vision (P Ͻ 0.05 versus SCA2, P Ͻ 0.001 versus SCA3), were less frequent in SCA1 than in SCA2 and SCA3. In contrast, increased ankle reflexes (P Ͻ 0.001 versus SCA2, P Ͻ 0.01 versus SCA3), spasticity (P Ͻ 0.01 versus SCA3), pale discs (P Ͻ 0.05 versus SCA3) and dysphagia (P Ͻ 0.05 versus SCA2 and SCA3) were more common in SCA1 (Table 1) .
Nerve conduction studies
Mean motor (tibial) nerve conduction velocities were in the low normal range in all groups (43 Ϯ 6 m/s with SCA1, 44 Ϯ 3 m/s with SCA2 and 44 Ϯ 3 m/s with SCA3). On an individual basis, motor nerve conduction velocities were MEPs were recorded in eight SCA1, 11 SCA2 and 18 SCA3 patients. Abnormal MEPs were significantly more frequent in SCA1 than in SCA2 and SCA3 patients. ***P Ͻ 0.001 versus SCA1 patients.
reduced in two out of nine SCA1 (22%; 33 m/s and 38 m/s), two out of 13 SCA2 (15%; 36 m/s and 39 m/s) and two out of 18 SCA3 patients (11%; 39 m/s and 37 m/s). There were no significant differences between SCA1, SCA2 and SCA3 patients. Mean amplitudes of the compound muscle action potentials of the tibial nerve were in the normal range in all groups. They were abnormally low (Ͻ5 mV) in none of the SCA1 patients, one of the SCA2 patients (8%) and in one of the SCA3 patients (6%), with no significant differences between the groups.
Mean sensory (sural) nerve conduction velocities were in the normal range in all groups (42 Ϯ 9 m/s with SCA1, 46 Ϯ 3 m/s with SCA2 and 44 Ϯ 9 m/s with SCA3). Abnormal results were obtained in one out of nine SCA1 (11%; 20 m/s), two out of 13 SCA2 (15%; 31 m/s and absent potentials) and in none out of 17 SCA3 patients, without any significant difference between the SCA1, SCA2 and SCA3 groups. In contrast, the mean amplitudes of sensory nerve action potentials of the sural nerve were abnormally low in all groups (6.7 Ϯ 4.9 µV with SCA1, 4.3 Ϯ 3.3 µV with SCA2 and 6.0 Ϯ 4.5 µV with SCA3). Abnormal results with amplitudes Ͻ10 µV were obtained in seven out of nine SCA1 (78%), 10 out of 13 SCA2 (77%) and in 13 out of 17 SCA3 patients (76%). Sensory neurography was not performed in one of the SCA3 patients. There were no significant differences between the groups.
Evoked potentials
Abnormal P100 waves in the VEPs, with latencies of Ͼ119 ms were obtained in seven out of nine SCA1 patients (78%), but only in four out of 11 SCA2 (36%) and four out of 16 SCA3 patients (25%) (P Ͻ 0.01, SCA1 versus SCA3). P100 responses were absent in a single SCA2 and a single SCA3 patient (Fig. 1) .
MEPs due to transcranial magnetic stimulation were abnormal in all eight SCA1 patients (100%), but only in two Ages and durations are given as means Ϯ SDs. *(1) P Ͻ 0.05, ** P Ͻ 0.01 and *** P Ͻ 0.001 versus SCA1, and *(2) P Ͻ 0.05 versus SCA2
out of 11 SCA2 (18%) and five out of 18 SCA3 patients (28%) (P Ͻ 0.001, SCA1 versus SCA2 and SCA3). Abnormalities consisted of delayed responses with latencies of Ͼ17.9 ms (six SCA1 patients, one SCA2 patient, five SCA3 patients) or absent responses (two SCA1 patients, one SCA2 patient, none of the SCA3 patients). The amplitudes of the MEPs did not differ significantly between the groups (Fig. 2) . Cortical SEPs after tibial nerve stimulation were abnormal in six out of eight SCA1 (75%), nine out of 13 SCA2 (69%) and in 13 out of 15 SCA3 patients (87%) with no significant differences between the groups. Abnormalities consisted of loss of cortical P40 responses in six of the SCA1 (75%), six of the SCA2 (46%), and four of the SCA3 patients (27%). Cortical P40 responses were delayed with latencies of Ͼ44.8 ms in none of the SCA1 patients, three of the SCA2 patients (23%) and nine of the SCA3 patients (60%) (P Ͻ 0.05, SCA1 versus SCA3) (Fig. 3) .
BAEPs were abnormal in four out of eight SCA1 (50%), five out of 12 SCA2 patients (42%) and 10 out of 16 SCA3 patients (63%). Abnormal BAEP findings consisted of loss of waves as well as increased interpeak intervals. There were no significant differences between the groups (Fig. 4) .
Discussion
ADCA-I comprises a group of neurodegenerative diseases that affect not only the cerebellum and its fibre connections, but also the peripheral nervous system and extracerebellar central pathways. The multisystemic nature of ADCA-I is reflected by electrophysiological features of predominantly sensory axonal neuropathy and abnormal evoked potentials in various modalities in most ADCA-I patients. Recently, genetic heterogeneity of ADCA-I was demonstrated, with SCA1, SCA2 and SCA3 representing the most common mutations. To extend our knowledge of the relationship between genotype and phenotype in ADCA-I, we compared electrophysiological features of SCA1, SCA2 and SCA3. The principal and novel finding of this study is that VEPs and MEPs following transcranial magnetic stimulation are abnormal in almost all SCA1, but in only a minority of SCA2 and SCA3 patients. In contrast, sensory axonal neuropathy and SEP or BAEP abnormalities are common features of all three mutations. These findings provide electrophysiological evidence that pyramidal and visual pathways are differentially affected in SCA1, SCA2 and SCA3 patients.
The VEP abnormalities included mild delay or loss of P100 responses. Earlier investigators studied mixed populations of patients with inherited or late onset ataxias and obtained variable results. Nousiainen et al. (1987) found delayed responses in almost all patients (Nousiainen et al., 1987) . Pedersen and Trojaborg (1981) found abnormal VEPs in two out of seven patients with ADCA, Nuwer et al. (1983) found them in two out of four patients, whereas two other studies reported normal responses in all patients with dominantly inherited ataxias with additional extracerebellar signs (Bird and Crill, 1981; Pedersen and Trojaborg, 1981; Nuwer et al., 1983; Wessel et al., 1993) . Interestingly, Sridharan (1983) reported VEP abnormalities in only one out of five patients with a dominant form of spinocerebellar degeneration that phenotypically resembled SCA2. Our VEP data correspond well to the frequent clinical observation of pale discs in SCA1, but not in SCA2 or SCA3 patients (Bürk et al., 1996) . However, involvement of the visual system in SCA1 is usually not associated with progressive loss of visual acuity. To our knowledge, there are no detailed neuropathological studies of the afferent visual pathways in ADCA-I. It is therefore not possible to correlate the VEP findings with neuropathological abnormalities of the visual system in ADCA-I. While demyelination is the cause of prolonged VEP latencies in multiple sclerosis, the pathophysiological mechanisms leading to delayed responses in degenerative diseases such as ADCA-I are less clear. The most probable mechanism appears to be depletion of predominantly large myelinated fibres.
Central motor conduction to the lower extremities was abnormal in all SCA1 patients, but in only a minority of SCA2 and SCA3 patients. The abnormalities included loss of MEPs or increase of central motor conduction times. Comparison of our data with those of earlier studies is difficult because these studies were done in clinically and genetically heterogeneous groups of patients. Thus, Claus et al. (1988) found abnormal MEPs in about two thirds of their patients with late onset ataxia. Mondelli et al. (1995) reported delayed MEPs in six out of nine ADCA patients and Wessel et al. (1993) found abnormally increased central motor conduction times in six out of eight patients with dominant ataxias presenting with additional extracerebellar symptoms (Claus et al., 1988; Wessel et al., 1993; Mondelli et al., 1995) .
The MEP abnormalities in SCA1 correspond well to the high frequency of pyramidal tract signs in this group (Bürk et al., 1996) . From a morphological point of view, the frequent finding of abnormal MEPs in SCA1 is surprising because the available neuropathological studies of SCA1 patients do not show involvement of the pyramidal tract in all cases. Greenfield (1954) who reviewed the neuropathology of the SCA1-linked Schut family noted pyramidal tract degeneration in only two out of eight cases (Schut, 1950; Greenfield, 1954) . Among recently published autopsies of SCA1 cases, only the patient of Gilman et al. (1996) had mild to moderate axonal loss and myelin pallor of the spinal pyramidal tract, while degenerative changes of the pyramidal tract were absent in the cases reported by Nino et al. (1980) , Spadaro et al. (1991) , Kameya et al. (1995) and Dürr et al. (1996) . These discrepancies between electrophysiological and neuropathological findings in SCA1 may be due to the fact that transcranial magnetic stimulation activates only a small subset of large myelinated pyramidal tract fibres. Routine neuropathological examination may fail to notice loss of these fibres. An alternative explanation would be that withdrawal of cerebellar excitatory drive might cause reduced excitability of the motor cortex in SCA1 patients (Meyer et al., 1994) . However, if this were the case, one would expect even more pronounced abnormalities in SCA2, since degeneration of cerebellar hemispheres is usually more severe in SCA2 than in SCA1 (Bürk et al., 1996) .
The low frequency of MEP abnormalities in SCA2 and SCA3 corresponds well to the preservation of the pyramidal tract in most autopsied SCA2 and SCA3 cases. Pyramidal tract degeneration was not reported in seven autopsied SCA2 patients (Orozco et al., 1989) . Among three autopsies of SCA3 patients pyramidal involvement was noted in only one case (Takiyama et al., 1994; Dürr et al., 1996) . In addition, the pyramidal tract was normal in two autopsy cases coming from a German family originally described by Becker et al. (1971) in which we have recently found the SCA3 mutation (unpublished data).
Cortical SEP abnormalities were present in the majority of our patients, confirming the results of a number of earlier studies (Pedersen and Trojaborg, 1981; Nuwer et al., 1983; Nousiainen et al., 1987; Dürr et al., 1993; Wessel et al., 1993) . There were no major differences between SCA1, SCA2 and SCA3 showing that SEP abnormalities are a common electrophysiological feature of the three mutations. However, the SEP alterations in SCA1 were more pronounced than in SCA3 with a higher frequency of absent responses. This observation points to more severe degeneration of somatosensory afferents in SCA1.
Autopsies of SCA1, SCA2 and SCA3 patients show degeneration of the posterior columns in SCA1, SCA2 and SCA3 suggesting that the SEP abnormalities are due to disturbed conduction at the spinal level (Greenfield, 1954; Becker et al., 1971; Nino et al., 1980; Orozco et al., 1989; Spadaro et al., 1992; Takiyama et al., 1994; Kameya et al., 1995; Dürr et al., 1996; Gilman et al., 1996) . However, the present data do not allow identification of the anatomical level of the somatosensory system at which conduction is disturbed, because we recorded only cortical potentials.
BAEP abnormalities were present in about half of our patients without major differences between the SCA1, SCA2, and SCA3 groups. Earlier studies in genetically heterogeneous groups of ataxia patients have obtained similar results (Pedersen and Trojaborg, 1981; Colletti et al., 1983; Nuwer et al., 1983; Knezevic and Stewart, 1985; Dürr et al., 1993; Wessel et al., 1993) . BAEP abnormalities included pathological wave latencies and interpeak intervals suggesting widespread involvement of the cochlear nerve and auditory pathways within the brainstem. BAEP abnormalities in patients with degenerative ataxia have often been interpreted to indicate the presence of olivopontocerebellar atrophy (Nuwer et al., 1983) . Olivopontocerebellar atrophy is a neuropathological term designating a type of cerebellar degeneration characterized by early and major involvement of pontine nuclei, middle cerebellar peduncles and inferior olives. The association of olivopontocerebellar atrophy and BAEP abnormalities is not supported by the results of the present study with BAEP abnormalities appearing in about half of SCA1, SCA2, and SCA3 patients. Evidence from autopsies and MRI studies show that olivopontocerebellar atrophy is a characteristic feature of SCA1 and SCA2, but not of SCA3 (Greenfield, 1954; Goldfarb et al., 1989; Orozco et al., 1989; Takiyama et al., 1994; Genis et al., 1995; Bürk et al., 1996) .
The nerve conduction studies revealed predominantly sensory axonal neuropathy with reduced amplitudes of sensory nerve action potentials in most patients. In contrast, compound muscle action potentials and nerve conduction velocities were usually normal. This finding is in agreement with earlier nerve conduction studies in ADCA-I patients with different mutations (Carenini et al., 1984; Nousiainen et al., 1988; Dürr et al., 1993 ). There were no major differences between SCA1, SCA2 and SCA3, although we cannot exclude the possibility that studies in larger groups of patients may reveal subtle differences between the mutations. Nevertheless, progressive loss of sensory axons appears to be a common feature of all three mutations.
The present data provide additional evidence that the SCA1, SCA2 and SCA3 groups are associated with characteristic phenotypes. Knowledge of the distinguishing electrophysiological features of the mutations will facilitate clinical diagnosis of these disorders. In addition, the data underline that the various CAG repeat disorders, although sharing common molecular mechanisms, cause distinct patterns of degeneration in the central nervous system.
